Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL93009 | 0.85 | — | — | |
| SCHEMBL4780885 | 0.85 | SMN1; SMN2 (0.49) | POLBHTTMEN1KMT2ALMNA | |
| Hydrochloric Acid SCHEMBL15548285 | 0.83 | — | — | |
| SCHEMBL29688205 | 0.83 | — | — | |
| SCHEMBL28469144 | 0.83 | — | — | |
| SCHEMBL27486778 | 0.82 | TAAR1 (0.48) | POLBHTTMEN1KMT2ALMNA | |
| Ethylene SCHEMBL27825937 | 0.81 | — | — | |
| Formamide SCHEMBL9014785 | 0.79 | POLB (0.48) | POLBHTTMEN1KMT2ALMNA | |
| Dimethylformamide SCHEMBL27604768 | 0.77 | RIPK1 (0.43) | POLBHTTALDH1A1HPGDSMN1; SMN2 | |
| Thiophene SCHEMBL27588267 | 0.77 | DPP4 (0.46) | POLBHTTKMT2ALMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9776971-B2 | Opioid and opioid-like compounds and uses thereof | TAIWANJ PHARMACEUTICALS CO., LTD. (TW) | 2017-10-03 | — | — | US | disclosed |
| EP-2987788-A1 | OPIOID AND OPIOID-LIKE COMPOUNDS AND USES THEREOF | Taiwanj Pharmaceuticals Co., Ltd. (TW) | 2016-02-24 | — | — | EP | disclosed |
| EP-1506174-B1 | USE OF NALTREXONE FOR TREATING KIDNEY AND LIVER DAMAGE | TAIWANJ PHARMACEUTICALS CO LTD (TW) | 2015-09-30 | — | — | EP | disclosed |
| US-8404706-B2 | Opioid and opioid-like compounds and uses thereof | JENKEN BIOSCIENCES, INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20120114599-A1 | OPIOID AND OPIOID-LIKE COMPOUNDS AND USES THEREOF | JENKEN BIOSCIENCES, INC. | 2012-05-10 | — | — | US | disclosed |
| US-20110243889-A1 | OPIOID AND OPIOID-LIKE COMPOUNDS AND USES THEREOF | JENKEN BIOSCIENCES, INC. | 2011-10-06 | — | — | US | disclosed |
| US-8017622-B2 | Opioid and opioid-like compounds and uses thereof | JENKEN BIOSCIENCES, INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-7923454-B2 | morphinan's such as 3-methoxy-17-allylmorphinan hydrobromide used for preventing or treating viral infections, septic shock, organ damage, neurological and cardiovascular disorders, neurodegenerative diseases and cancers | JENKEN BIOSCIENCES, INC. (US) | 2011-04-12 | — | — | US | disclosed |
| US-20090169508-A1 | OPIOID AND OPIOID-LIKE COMPOUNDS AND USES THEREOF | JENKIN BIOSCIENCES, INC. | 2009-07-02 | — | — | US | disclosed |
| US-7501433-B2 | Opioid and opioid-like compounds and uses thereof | JENKEN BIOSCIENCES, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-20050261329-A1 | Opioid and opioid-like compounds and uses thereof | JENKEN BIOSCIENCES, INC. | 2005-11-24 | — | — | US | disclosed |
| US-20050107415-A1 | Opioid and opioid-like compounds and uses thereof | JENKEN BIOSCIENCES, INC. | 2005-05-19 | — | — | US | disclosed |
| EP-1506174-A2 | OPIOID AND OPIOID-LIKE COMPOUNDS AND USES THEREOF | Jenken Biosciences, Inc. (US) | 2005-02-16 | — | — | EP | disclosed |
| WO-2003097608-A2 | OPIOID AND OPIOID-LIKE COMPOUNDS AND USES THEREOF | JENKEN BIOSCIENCES, INC. (US) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120114599-A1 | OPIOID AND OPIOID-LIKE COMPOUNDS AND USES THEREOF | OPRK1, OPRL1, OPRM1 | POLB 4178/4885HTT 3100/4885MEN1 4871/4885 |
| US-20090169508-A1 | OPIOID AND OPIOID-LIKE COMPOUNDS AND USES THEREOF | OPRK1, OPRL1, OPRM1 | POLB 4178/4885HTT 3100/4885MEN1 4871/4885 |
| US-20050107415-A1 | Opioid and opioid-like compounds and uses thereof | OPRL1, OPRK1, OPRM1 | POLB 4528/4885HTT 3658/4885MEN1 4869/4885 |
| US-20050261329-A1 | Opioid and opioid-like compounds and uses thereof | OPRK1, OPRL1, OPRM1 | POLB 4178/4885HTT 3100/4885MEN1 4871/4885 |
| US-20110243889-A1 | OPIOID AND OPIOID-LIKE COMPOUNDS AND USES THEREOF | OPRL1, OPRK1, OPRM1 | POLB 4528/4885HTT 3658/4885MEN1 4869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.